(Q37876404)

24 August 2017

1 reference

title

Interleukin-23: a key cytokine in inflammatory diseases (English)

1 reference

24 August 2017

0 references

0 references

Emilie Duvallet

1

1 reference

24 August 2017

Luca Semerano

2

1 reference

24 August 2017

Eric Assier

3

1 reference

24 August 2017

Géraldine Falgarone

4

1 reference

24 August 2017

Marie-Christophe Boissier

5

1 reference

24 August 2017

language of work or name

English

0 references

publication date

17 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

43

1 reference

24 August 2017

7

1 reference

24 August 2017

503-511

1 reference

Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis

24 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Interleukin-35: odd one out or part of the family?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

What kind of message does IL-12/IL-23 bring to macrophages and dendritic cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORgammat in gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

γδ T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

CCR6 is required for IL-23-induced psoriasis-like inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Infection, inflammation, and chronic diseases: consequences of a modern lifestyle.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Monoclonal Anti–Interleukin 23 Reverses Active Colitis in a T Cell–Mediated Model in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Toll-like Receptor 7 Mitigates Lethal West Nile Encephalitis via Interleukin 23-Dependent Immune Cell Infiltration and Homing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

T helper 17 cells get the NOD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Reconciling id, ego, and superego within interleukin-23.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Cytokines: from gut inflammation to colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Paneth cells: leukocyte-like mediators of innate immunity in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

The clinical role of IL-23p19 in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Interleukin-23 receptor gene variants in Hungarian systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

The association between interleukin-23 receptor gene polymorphisms and systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Differential Regulation of Interleukin (IL)-12 p35 and p40 Gene Expression and Interferon (IFN)-γ–primed IL-12 Production by IFN Regulatory Factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

T-bet is essential for encephalitogenicity of both Th1 and Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.577093

10.3109/07853890.2011.577093

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference